Abstract 241P
Background
The aims of this study were to investigate the genetic alternations of locally advanced cervical cancer and to elucidate the associations among clinico-pathological factors, genomic alterations and clinical outcomes of the patients receiving concurrent chemo-radiotherapy (CCRT). We performed the targeted sequencing for somatic mutations across the hotspot regions of 50 cancer-related genes using biopsy specimens.
Methods
Seventy-six patients diagnosed as FIGO Stage III to IVA cervical cancer underwent radiation therapy or CCRT at National Cancer Center Hospital between January 2008 and December 2017. All the patients received external beam radiation therapy and brachytherapy. The most of chemotherapy regimen was cisplatin. Genomic DNAs extracted from formalin-fixed and paraffin-embedded tumor tissues were subjected to the analysis using an Ion AmpliSeq TM Cancer Hotspot Panel v2. Six patients were disqualified from this study because of low quality DNA. Oncogenic or pathogenic variants registered in the OncoKB and the ClinVar databases were defined as mutations. In the present study, gene aberrations with evidence levels 1A-3A were judged as actionable mutation for molecular targeted drugs. HPV infection was detected by in-situ hybridization and genotypes were determined by Sanger sequencing.
Results
Seventy patients were enrolled in this study. Sixty-five patients (93%) had squamous cell carcinoma. Pathogenic mutations were detected in 47 cases (67%); frequencies of gene alterations in PIK3CA (51%), FBXW7 (10%), PTEN (7.1%) and TP53 (5.7%). The clinical factor associated with poor survival was the tumor diameter. Cox regression analysis showed the tumor diameter larger than 70mm were associated with shorter progression-free survival (PFS) (Hazard ratio = 2.96, P = 0.0048) in multivariate analysis. Patients infected without HPV16/18 had poor PFS than those with HPV 16/18 (Log-rank P = 0.025). TP53 mutants were correlated with poor PFS (Log-rank P = 0.044). Thirty-seven patients (53%) have actionable genomic alternations.
Conclusions
Larger tumor diameter, non HPV16/18 and TP53 mutants correlated with worse outcomes to CCRT in the Japanese patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract